Youcai Zhang——Professor |
|
|
Nationality:
|
CHINA
|
|
Phone:
|
022-87401830
|
|
Email:
|
youcai.zhang@tju.edu.cn
|
|
Office:
|
Room 3107, Building 24, Tianjin University
|
|
School:
|
School of Pharmaceutical Science and Technology
|
|
ResearcherID:
|
|
|
Group weblink
|
|
Education Experience
| 2011 | Ph. D. Pharmacology and Toxicology | University of Kansas Medical Center |
| 2013-2014 | Postdoctoral Bioengineering | University of California San Francisco |
Professional Experience
| 2011-2013 | Associate Scientist | Elan Pharmaceutics Inc |
| 2013-2014 | Principle Scientist | Apricity Therapeutics |
Research Area
Honors and Awards
| Associate Editor, Toxicological Sciences |
| Editor board member, Journal of Lipid Research |
Patents
Highlighted Publications
| 1. Wang X, Luo J, Han L, Xu T, Wang H, Zhang M, Li G, Li X, Zhang W, Zhang Y (2025). FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis. Hepatology (in press) （唯一通讯） |
| 1. Wang X, Klaassen CD, Chen X, Zhang Y* (2025). Pathological and therapeutic roles of bile acid metabolism and signaling in hepatocellular carcinoma: insights from human and mouse studies. Pharmacological Reviews, 77(5): 100073.（唯一通讯） |
| Xu T, Li X, Zhao W, Wang X, Jin L, Feng Z, Li H, Zhang M, Tian Y, Hu G, Yue Y, Dai X, Shan C, Zhang W, Zhang C, Zhang Y. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis, Journal of Experimental&Clinical Cancer Research, 2024 (主通讯） |
| Zhao W, Wang X, Han L, Zhang C, Wang C, Kong D, Zhang M, Xu T, Li G, Hu G, Luo J, Yee SW, Yang J, Stahl A, Chen X, Zhang Y. SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis, Nature Communications, 2024 （主通讯） |
| Hui Xiong, Chunze Zhang, Lifeng Han, Tong Xu, Khawar Saeed, Jing Han, Jing Liu, Curtis D. Klaassen, Frank J Gonzalez, Yuanfu Lu, Youcai Zhang, Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity, Hepatology, 2022 （主通讯） |